Mar 10, 2022
Dr. John Dobak is the President and CEO of DermTech which is leading the genomic revolution in dermatology to more accurately determine the presence of skin cancer. Their noninvasive platform changes the protocol for assessing a suspicious mole from visual review and surgically removing tissue to genomic analysis and using broader objective data before treatment is determined.
John elaborates, "Genomics is fundamentally changing the way medicine is practiced, and it is particularly changing cancer care and how cancer is detected and treated. We're really bringing that revolution to the dermatologist. We do that with our noninvasive genomics platform. We have something called the Smart Sticker, which is a special adhesive patch that can collect the sample of the skin noninvasively. And it feels a lot like scotch tape, you just press it on the skin, and you lift it off. And from that skin sample, the tissue we've collected, we can run a variety of genomic analyses, and that allows us to determine whether or not cancer might be present in a mole, for example."
"Our first product in the market is specifically for melanoma skin cancer. That's the most deadly of skin cancers. It's the most concerning skin cancer. It's a real problem. Doctors don't want to miss melanoma because it can lead to higher mortality in a patient. But melanoma skin cancer can also be cured very effectively if it's found early. So, the 99% of patients that have melanoma detected at the earliest stages have a 5 to 10-year survival."
@DermTech #DermTech #Dermatology #DermTechIt #PrecisionGenomics #SkinExams #Melanoma #SkinCancer #MelanomaDetection #EarlyDetection #SkinHealth #SanDiego